GSK names McNamara as CEO of consumer health spinoutGlaxoSmithKline has said that Brian McNamara – currently head of its three-year-old consumer health joint venture with Pfizer Share XGSK names McNamara as CEO of consumer health spinouthttps://pharmaphorum.com/news/gsk-names-mcnamara-as-ceo-of-consumer-health-spinout/
EMA starts review of latecomer GSK/Sanofi COVID-19 vaccineThe EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started Share XEMA starts review of latecomer GSK/Sanofi COVID-19 vaccinehttps://pharmaphorum.com/news/ema-starts-review-of-latecomer-gsk-sanofi-covid-19-vaccine/
GSK unveils plan for life sciences cluster at Stevenage campusGlaxoSmithKline wants to sell more than a third of the space at its R&D campus in Stevenage, UK, Share XGSK unveils plan for life sciences cluster at Stevenage campushttps://pharmaphorum.com/news/gsk-unveils-plan-for-life-sciences-cluster-at-stevenage-campus/
FDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemiaSafety concerns seem to have scuppered any hope of a near-term approval for FibroGen and AstraZeneca’s roxadustat for Share XFDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemiahttps://pharmaphorum.com/news/fda-adcomm-turns-down-fibrogen-azs-roxadustat-for-ckd-anaemia/
GSK cancer head Hoos exits, takes top role at biotech ScorpionGlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role Share XGSK cancer head Hoos exits, takes top role at biotech Scorpionhttps://pharmaphorum.com/news/gsk-cancer-head-hoos-exits-takes-top-role-at-biotech-scorpion/
GSK backs CEO Walmsley, rejecting Elliott’s call to change boardGlaxoSmithKline’s board had responded to the broadside attack delivered by activist investor Elliott Management yesterday, saying it stands Share XGSK backs CEO Walmsley, rejecting Elliott’s call to change boardhttps://pharmaphorum.com/news/gsk-backs-ceo-walmsley-rejecting-elliotts-call-to-change-board/
Elliott fires broadside at GSK in wake of investor updateGlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm’s prospects at Share XElliott fires broadside at GSK in wake of investor updatehttps://pharmaphorum.com/news/elliott-fires-broadside-at-gsk-in-wake-of-investor-update/
Sanofi doubles down on mRNA jabs with €400m-a-year R&D driveSanofi has just significantly increased its investment in mRNA vaccine development, earmarking €400 million ($475 million) a year Share XSanofi doubles down on mRNA jabs with €400m-a-year R&D drivehttps://pharmaphorum.com/news/sanofi-doubles-down-on-mrna-jabs-with-e400m-yearly-rd-drive/
AZ, Sanofi prep filings for one-shot RSV antibody after trial winAstraZeneca and Sanofi now have the data they need in hand to press ahead with regulatory filings next Share XAZ, Sanofi prep filings for one-shot RSV antibody after trial winhttps://pharmaphorum.com/news/az-sanofi-prep-filings-for-one-shot-rsv-antibody-after-trial-win/
